S2, E6: iOmx and shaking up the immuno-oncology field with CEO Apollon Papadimitriou, Professor Phillip Beckhove (RCI) and Jared Holz (Mizuho)

S2, E5: Cerevance and a new approach to Parkinson's disease with CEO Craig Thompson and CNS expert Prof Karl Kieburtz (URMC, Clintrex)

S2, E4: Sparrow Pharmaceuticals and tackling the ravaging effects of steroids with founder David Katz and experts Dr Peter Merkel (UPenn), Dr Leon Henderson-MacLennan (InThought)

S2, E3: Ray Therapeutics leveraging optogenetics to tackle vision loss with CEO Paul Bresge and Dr José-Alain Sahel (University of Pittsburgh)

S2, E2: Fauna Bio tapping animal evolution and AI for drug development with CEO Ashley Zehnder and Prof Elinor Karlsson, Broad Institute (MIT/Harvard)

S2, E1: Mana.bio and programmable lipid nanoparticles with CEO Yogev Debbi and RNA expert Dr Barry Ticho

S1, E6: Alltrna and tRNA therapeutics for rare genetic diseases with CEO Michelle Werner and rare diseases expert Dr David Weinstein

S1, E5: Arialys and a neuropsychiatry drug revival with CEO Jay Lichter and experts Marty Jefson (Pinteon) and Dr Leon Henderson-MacLennan (InThought)

S1, E4: Synchron and breakthrough brain implants with CEO Dr Tom Oxley, CCO Kurt Haggstrom and experts Dr Elad Levy (UB), Dr David Putrino (Mount Sinai)

S1, E3: eGenesis and xenotransplantation with CEO Mike Curtis and Dr Adam Griesemer, NYU

S1, E2: Ochre Bio with CEO/Co-founder Jack O'Meara and liver expert Dr Scott Friedman, Mount Sinai

S1, E1: Empress Therapeutics with CEO/Co-founder Jason Park + experts Prof Jim Collins, MIT and Dr Leon Henderson-MacLennan, InThought

S3, E6: Veradermics puts hair loss back on the investor agenda with $150 million Series C - with CEO Dr Reid Waldman and InThought's Julie Hoggatt

S3, E5: Special Analysis: What's going on with European Biotech? - Reporting from BioEurope in Vienna

S3, E4: ReproNovo’s strategic trash-to-treasure bet on fertility and reproductive health - with CEO Jean Marie Duval

S3, E3: AltruBio’s Cinderella story from bankruptcy talks to a $225M Series B to tackle autoimmune diseases - with CEO Dr Judy Chou

S3, E2: The Biotech Bromance: Serial CEO and Investor’s 20‑Year Journey of Building Biotechs with Steve Butts, Arrivo Bio and Dave Adair, Solas BioVentures

S3, E1: How Xaira Therapeutics went from incubation to a billion dollar launch - with Vik Bajaj, CEO Foresite Labs

It's been a while! Season 3 update from Surani

Raising Biotech Trailer